This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT)

This study is not yet open for participant recruitment.
See Contacts and Locations
Verified April 2011 by Tel-Aviv Sourasky Medical Center
Information provided by:
Tel-Aviv Sourasky Medical Center Identifier:
First received: April 20, 2011
Last updated: NA
Last verified: April 2011
History: No changes posted
Long-term follow-up studies have demonstrated significant late toxicities of total body irradiation (TBI), which are most marked in children radiated at a young age. Growth failure, decline in cognitive function, and endocrine abnormalities have all been described. Good outcomes can be achieved with alkylating agents only as a preparative regimen. This plan will use a combination of busulfan and cyclophosphamide (Bu/Cy) with or without antithymocyte globulin (ATG) to reduce the late toxicities of therapy that includes TBI.

Condition Intervention Phase
Acute Leukemias Chronic Leukemias Myelodysplastic Syndrome Juvenile Myelomonocytic Leukemia Drug: Busulfan/Cyclophosphamide Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Treatment Plan for Hematologic Malignancies Using Intravenous Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide to Examine Results, Success and Side Effects of Treatment With Chemotherapy Only, as a Preparative Therapy for Patients With Cord Blood Transplants

Resource links provided by NLM:

Further study details as provided by Tel-Aviv Sourasky Medical Center:

Primary Outcome Measures:
  • Overall survival [ Time Frame: Five years ]

Secondary Outcome Measures:
  • Disease free survival [ Time Frame: Five years ]

Estimated Enrollment: 10
Study Start Date: June 2011
Estimated Study Completion Date: June 2019
Estimated Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Busulfan/Cyclophosphamide Drug: Busulfan/Cyclophosphamide

Conditioning regimen:

Cyclophosphamide 50mg/kg/day for 4 days + Busulfan 0.8-1.0mg/kg/day for 4 days.

Other Name: Cytoxan


Ages Eligible for Study:   up to 21 Years   (Child, Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Suitable cord blood from matched unrelated or related donor.
  • Cardiac (Echo/EKG): shortening fraction ≥ 27%
  • Electrolytes within normal CCHMC limits.
  • Pulmonary function tests: DLCO ≥ 50%
  • Renal: creatinine clearance/GFR ≥ 60 ml/minute/1.73m2
  • Lumbar puncture: no leukemic infiltrate.
  • CBC: ANC ≥ 1000ml and unsupported platelet count of ≥ 50,000/ml
  • Documented HSV and CMV titers, Hepatitis B surface antigen, Hepatitis C by serology, HIV by serology: all negative.
  • Hepatic transaminases < 2.5x normal; Total bilirubin < 2 mg/dl Patients who do not meet above organ function criteria (liver, cardiac, renal), due to the presence of a tumor compromising these organs, may have exception made for these criteria and remain eligible for treatment plan after consultation with Program Director of Blood and Marrow Transplant

Exclusion Criteria:

  • Patients with neoplastic or non-neoplastic disease of any major organ system that would compromise their ability to withstand the pre-transplant conditioning regimen.
  • Patients with uncontrolled (culture or biopsy positive) infections requiring intravenous antivirals, antibiotics, or antifungals. Patients on prolonged antifungal therapy with a history of fungal infection should be considered for a non-myeloablative protocol.
  • Patients who are pregnant or lactating. Patients of childbearing potential must practice an effective method of birth control while participating on this treatment plan.
  • HIV seropositive patients
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

Responsible Party: Menachem Bitan, Tel-Aviv Sourasky Medical Center Identifier: NCT01339988     History of Changes
Other Study ID Numbers: TASMC-11-MB-442-CTIL
Study First Received: April 20, 2011
Last Updated: April 20, 2011

Keywords provided by Tel-Aviv Sourasky Medical Center:

Additional relevant MeSH terms:
Myelodysplastic Syndromes
Leukemia, Myelomonocytic, Juvenile
Neoplasms by Histologic Type
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions
Leukemia, Myeloid
Myelodysplastic-Myeloproliferative Diseases
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists processed this record on August 18, 2017